WT1 and breast cancer: This study evaluated the safety, immunogenicity, and preliminary clinical activity of the WT1 antigen combined with GSK’s proprietary immunostimulant AS15 (WT1-immunotherapeutic) administered to women with BC during standard neoadjuvant treatment.